FCHC Behavioral Health Inpatient

FCHC Behavioral Health Inpatient is a SAMHSA-registered addiction-treatment facility located at Wahiawa, HI. The specific care levels offered by FCHC Behavioral Health Inpatient should be confirmed directly with the admissions team. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at FCHC Behavioral Health Inpatient

Care-level specifics for FCHC Behavioral Health Inpatient are not well-documented in the public SAMHSA record; a direct conversation with the admissions team is the reliable way to confirm what the facility actually provides. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of FCHC Behavioral Health Inpatient's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

Payment and insurance posture: Payment and insurance specifics for FCHC Behavioral Health Inpatient are not fully documented in the SAMHSA registry — a direct admissions conversation is the reliable way to confirm what forms of payment are accepted and at what network-contract level. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Before you call

Pre-admission due-diligence for FCHC Behavioral Health Inpatient: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via HI behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether FCHC Behavioral Health Inpatient offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.